NEW YORK, May 30 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. (Celtic Pharma), a global private equity investment firm focused on the biotechnology and pharmaceutical industries, announced today that it has engaged Richard Lewis Communications, Inc. (RLC) and its affiliate, TS Communications Group, LLC, for a national, regional and local public relations program targeting patient recruitment efforts into multiple, ongoing clinical trials for XERECEPT(R) (corticorelin acetate injection), a Phase III clinical compound for the treatment for edema associated with brain cancer.
Dr. Patrick C. O'Connor, Managing Director and Head of Clinical Development at Celtic Pharma Development Services Bermuda Ltd., said, "Celtic Pharma, which acquired the exclusive worldwide rights to XERECEPT from Neurobiological Technologies, is pleased to be working with the RLC team. The program goal is to increase the visibility and awareness of the potential of this exciting new drug for the treatment of brain tumor related edema. RLC's communications efforts will encourage patients and their families to learn more about XERECEPT clinical trials enrollment in both the United States and Canada."
Gregory Tiberend, EVP & COO of RLC and head of its Life Sciences Group, said, "Celtic Pharmaceutical Holdings' selection of RLC for XERECEPT reflects the significant momentum we have gained in the life science sector. Public and private companies continue to work with us because of our dedicated team, our focus on client service and the results we generate for them."
About XERECEPT(R)
XERECEPT(R) works to reduce edema, defined as an abnormal increase in brain water content, which can have dire consequences, potentially leading to brain ischemia (stroke), herniation, and death. Based on clinical data to date, XERECEPT is believed to be a comparably efficacious and safer alternative to the myriad of adverse effects of corticosteroids currently being employed in the treatment of cerebral edema. XERECEPT is currently in three phase III clinical trials in the United States and Canada for the treatment of edema associated with brain cancer. XERECEPT is being developed by Celtic Pharmaceutical Holdings L.P. in collaboration with Neurobiological Technologies .
About Celtic Pharmaceutical Holdings L.P.
Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) is a global private equity investment firm focused on the biotechnology and pharmaceutical industries. Celtic Pharma was founded by Stephen Evans-Freke and John Mayo, CBE, and is based in Bermuda, with offices in New York and London. Celtic Pharma acquires and invests in late stage pharmaceutical programs and drives these programs through the final stages of regulatory approval. Celtic Pharma's aim is to bridge the gap between the established pharmaceutical companies' new product pipeline crisis and the biotech industry's capital drought. For further information, please visit Celtic Pharma's website at www.celticpharma.com.
About Richard Lewis Communications, Inc.
Richard Lewis Communications, Inc., based in New York City, focuses on serving the communications needs of healthcare, biotechnology, financial services, business services and marine recreational clients. RLC provides senior-level strategic counsel backed by results driven program execution. Services include public relations, management counsel, corporate positioning, pre-IPO public relations programs, and venture capital relations. In addition to its strategic affiliation with TS Communications Group LLC of Rye, NY, RLC has other affiliate relationships in New York, San Francisco, Tokyo, Paris and Fort Lauderdale, FL. For more information, visit www.rlcinc.com
Richard Lewis Communications, Inc.
CONTACT: Gregory Tiberend, EVP & COO, RLC Life Sciences Group,+1-212-827-0020, gtiberend@rlcinc.com, for Richard Lewis Communications,Inc.; Kathy Armstrong, Investor Relations, Celtic Pharmaceutical ManagementL.P., +1-212-616-4042, kathy@celticpharma.com
